R. Ochoa-Azze

A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles

J. L. Pérez, Guang-Wu Chen, L. González, 2021, RSC chemical biology.

Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba.

V. Verez-Bencomo, R. Ochoa-Azze, L. García-Imía, 2018, MEDICC review.

Cross-protection induced by VA-MENGOC-BC® vaccine

R. Ochoa-Azze, 2018, Human vaccines & immunotherapeutics.

A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles †‡ RSCChemical Biology

J. L. Pérez, Guang-Wu Chen, Y. Ramos, 2022 .

Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial

A. Calcagno, V. Ghisetti, C. Valenzuela-Silva, 2022, The Lancet Respiratory Medicine.

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

Guang-Wu Chen, C. A. González-Delgado, C. Valenzuela-Silva, 2021, Vaccine.

A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial

B. Marcheco-Teruel, Guang-Wu Chen, C. Valenzuela-Silva, 2021, The Lancet Regional Health - Americas.

A single dose of SARS CoV 2 FINLAY FR 1A dimeric RBD recombinant vaccine enhances neutralization response in COVID19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial

B. Marcheco-Teruel, Guang-Wu Chen, C. Valenzuela-Silva, 2021, medRxiv.